Table 7.
Five-year disease-specific survival data by treatment modality and location for 10,833 patients with gastrointestinal stromal tumors from the Surveillance, Epidemiology, and End Results (SEER) database 2000–2018.
| Location | 5-Year Disease-Specific Survival, (%, 95 Confidence Interval) | ||
|---|---|---|---|
| Surgery | Chemotherapy ± Surgery | Adjuvant Radiation | |
| Esophagus # | 79.6 (57.4–91.1) | 62.1 (33–81.5) | + |
| Stomach | 88.4 (87.2–89.5) | 74.4 (72.1–76.5) | 70.7 (33.7–89.5) |
| Small Intestine | 83.7 (81.9–85.3) | 81.7 (79–84) | 57.1 (17.2–83.7) |
| Cecum # | 79.5 (57.4–90.9) | 64.8 (25.3–87.2) | + |
| Appendix # | + | + | + |
| Ascending Colon # | 43.9 (21.7–64.2) | 33.3 (5.3–66.4) | + |
| Hepatic Flexure # | 48.5 (14.4–76.3) | + | + |
| Transverse Colon # | 92.3 (56.6–98.9) & | 83.3 (27.3–97.5) | + |
| Splenic Flexure # | + | + | + |
| Descending Colon # | 73.6 (49.5–87.5) | 51.1 (13.8–79.7) | + |
| Sigmoid Colon # | 77.1 (59.1–87.9) | 80 (40.9–94.6) | + |
| Large Intestine, NOS # | 67.6 (38.6–85.1) | 60 (79–85.5) | + |
| Rectosigmoid Junction # | 78.8 (38.1–94.3) & | 85.7 (33.4–97.9) | + |
| Rectum # | 90.3 (84.3–94) | 88.5 (80.5–93.4) | 66.6 (33.1–86.1) |
| Anus, Anal Canal, AD # | 88.9 (43.3–98.4) & | + | + |
Abbreviations: NOS, Not otherwise specified; AD, Anoderm; +, Statistics could not be calculated; &, Width of the confidence interval is more than that if normal approximation is applied; #, Due to the small sample size, the survival data from these locations should be interpreted cautiously.